Comparative Pharmacology
Head-to-head clinical analysis: DIFICID versus MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFICID versus MILI.
DIFICID vs MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
MILI is a novel oral direct renin inhibitor that binds to the active site of renin, preventing the conversion of angiotensinogen to angiotensin I, thereby reducing plasma renin activity and angiotensin I and II levels.
200 mg (tablet) orally twice daily for 10 days.
Not applicable; MILI is an unrecognized drug.
None Documented
None Documented
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Primarily renal excretion of unchanged drug (60-80%) with minor biliary/fecal elimination (10-20%).
Category C
Category C
Antibiotic
Antibiotic